Article
Iris-claw myopic IOL shows promise during ongoing FDA trial
Author(s):
San Francisco-In ongoing FDA clinical trial follow-up, the iris-claw myopic IOL (Artisan/Verisyse, Ophtec/AMO) continues to be associated with excellent refractive and visual outcomes along with outstanding safety and high patient satisfaction, said Elizabeth A. Davis, MD, FACS, at the American Society of Cataract and Refractive Surgery annual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
